Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19
Open Access
- 14 April 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8, 642313
Abstract
Macrolides (e.g., erythromycin, fidaxomicin, clarithromycin, and azithromycin) are a class of bacteriostatic antibiotics commonly employed in medicine against various gram-positive and atypical bacterial species mostly related to respiratory tract infections, besides they possess anti-inflammatory and immunomodulatory effects. Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2). It was first detected in Wuhan, Hubei, China, in December 2019 and resulted in a continuing pandemic. Macrolides have been extensively researched as broad adjunctive therapy for COVID-19 due to its immunostimulant abilities. Among such class of drugs, azithromycin is described as azalide and is well-known for its ability to decrease the production of pro-inflammatory cytokines, including matrix metalloproteinases, tumor necrosis factor-alpha, interleukin (IL)-6, and IL-8. In fact, a report recently published highlighted the effectiveness of combining azithromycin and hydroxychloroquine for COVID-19 treatment. Indeed, it has been underlined that azithromycin quickly prevents SARS-CoV-2 infection by raising the levels of both interferons and interferon-stimulated proteins at the same time which reduces the virus replication and release. In this sense, the current review aims to evaluate the applications of macrolides for the treatment of COVID-19.Keywords
This publication has 75 references indexed in Scilit:
- Macrolide Therapy in Respiratory Viral InfectionsMediators of Inflammation, 2012
- Suppressive Effects of Azithromycin on Zymosan-Induced Production of Proinflammatory Mediators by Human Corneal Epithelial CellsInvestigative Ophthalmology & Visual Science, 2010
- Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory MedicationsClinical Microbiology Reviews, 2010
- Azithromycin induces anti-viral responses in bronchial epithelial cellsEuropean Respiratory Journal, 2010
- Randomized Dose-Ranging Controlled Trial of AQ-13, a Candidate Antimalarial, and Chloroquine in Healthy VolunteersPLoS Clinical Trials, 2007
- Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral ActivitiesJournal of Medicinal Chemistry, 2006
- Effect of clarithromycin on rhinovirus-16 infection in A549 cellsEuropean Respiratory Journal, 2006
- In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquineBiochemical and Biophysical Research Communications, 2004
- Azithromycin Clinical PharmacokineticsClinical Pharmacokinetics, 1993
- The pharmacokinetics of azithromycin and their clinical significanceEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991